Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026
Gothenburg, Sweden, April 17, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the Nomination Committee proposes the election of Jan‐Fredrik Backman as new Vice Chairperson and James Gamgort as new Board member at the Annual General Meeting in 2026. The Nomination Committee further proposes the re‐election of Chairperson Carola Lemne and Board members Gunnar Olsson, Rein Piir and Veronica Wallin. Christer Nordstedt has declined re‐election.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Kristina Torfgård, CEO, presents at Redeye Healthcare Day 2026
Kristina Torfgård, CEO, presented at Redeye Healthcare Day on April 14, 2026. Presentation in Swedish.
Read More >